GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
10 juin 2022 03h00 HE
|
Global Blood Therapeutics, Inc.
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at...
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
06 juin 2022 10h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced that it is...
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
06 juin 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease GBT601 is a...
GBT Announces New Employment Inducement Grants
02 juin 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2022, the compensation committee of GBT’s board of...
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
01 juin 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
Conference call and webcast will include data presented at EHA 2022 and business and R&D updates Company to also participate in the William Blair and Goldman Sachs investor conferences SOUTH SAN...
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
12 mai 2022 10h00 HE
|
Global Blood Therapeutics, Inc.
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) --...
GBT Announces New Employment Inducement Grants
05 mai 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2022, the compensation committee of GBT’s board of...
GBT Announces Participation in Upcoming Investor Conferences
05 mai 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in fireside chats at the following investor...
GBT Reports First Quarter 2022 Financial Results
04 mai 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4...
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
28 avr. 2022 08h20 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient...